RESEARCH ARTICLE

Incidence of T315I mutation in BCR/ABL-positive CML and ALL patients

  • Fatemeh Norozi 1 ,
  • Javad Mohammadi-asl 2 ,
  • Tina Vosoughi 1 ,
  • Mohammad Ali Jalali Far 1 ,
  • Amal Saki Malehi 1 ,
  • Najmaldin Saki , 1
Expand
  • 1. Health Research Institute, Thalassemia and Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  • 2. Department of Medical Genetics, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Received date: 07 Jun 2016

Accepted date: 02 Aug 2016

Published date: 04 Nov 2016

Copyright

2016 Higher Education Press and Springer-Verlag Berlin Heidelberg

Abstract

OBJECTIVES: Targeted therapy of Philadelphia-positive ALL and CML patients using imatinib (IM) has caused significant changes in treatment course and has increased the survival of patients. A small group of patients show resistance to IM. Acquired mutations in tyrosine kinase domain of BCR-ABL protein are a mechanism for development of resistance. T315I is one of the most common acquired mutations in this domain, which occurs in ATP binding site and inhibits the formation of hydrogen bond with IM. The aim of this study was to evaluate the prevalence of this mutation in BCR/ABL-positive CML and ALL patients.

METHODS: To conduct this study, 60 BCR-ABL-positive patients (including 50 CML and 10 ALL patients) who were subject to treatment with IM were selected. After taking the samples, presence of T315I mutation was assessed using ARMS-PCR on cDNA and its polymorphism was evaluated by sequencing.

RESULTS: The results showed that among 60 patients, only three patients had T315I mutation, which was detected using ARMS technique. The three patients bearing mutation were afflicted with CML and no significant association was found between blood parameters with duration of treatment in presence of mutation.

CONCLUSIONS: The mutation was found in three CML patients, which indicated lower likelihood and diagnostic value of this mutation in ALL patients. Given the negative direct sequencing results in T315I patients, it can be concluded that ARMS-PCR is a more sensitive technique when the number of cancer cells is low in patients during treatment.

Cite this article

Fatemeh Norozi , Javad Mohammadi-asl , Tina Vosoughi , Mohammad Ali Jalali Far , Amal Saki Malehi , Najmaldin Saki . Incidence of T315I mutation in BCR/ABL-positive CML and ALL patients[J]. Frontiers in Biology, 2016 , 11(5) : 404 -411 . DOI: 10.1007/s11515-016-1423-1

Abbreviations

JAK-STAT: Janus kinases/signal transducers and activators of transcription; MAPK: Mitogen-activated protein kinase; NF-kB: Nuclear factor kB; PI-3 kinase: Phosphatidylinositol 3-kinase.

Acknowledgements

This work was financially supported by grant TH94/8 from the Vice Chancellor for Research Affairs of the Ahvaz Jundishapur University of Medical Sciences. This paper is issued from the thesis of Fatemeh Norozi.

Compliance with ethics guidelines

The authors declare that they have no conflict of interest. All the procedures performed in the studies involving human participants were in accordance with the ethical standards of local ethics committee of the Ahvaz Jundishapur University of Medical Sciences (IR.AJUMS.REC.1394.342) as well as 1964 Helsinki declaration. Written informed consent was obtained from all patients and normal subjects.
1
Apperley J F (2007). Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol, 8(11): 1018–1029

DOI PMID

2
Bhojwani D, Yang J J, Pui C H (2015). Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am, 62(1): 47–60

DOI PMID

3
Branford S, Melo J V, Hughes T P (2009). Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood, 114(27): 5426–5435

DOI PMID

4
Chomel J C, Sorel N, Bonnet M L, Bertrand A, Brizard F, Roy L, Guilhot F, Turhan A G (2010). Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia. Leuk Lymphoma, 51(11): 2103–2111

DOI PMID

5
Donato N J, Wu J Y, Stapley J, Lin H, Arlinghaus R, Aggarwal B B, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M (2004). Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res, 64(2): 672–677

DOI PMID

6
Druker B J, Guilhot F, O’Brien S G, Gathmann I, Kantarjian H, Gattermann N, Deininger M W, Silver R T, Goldman J M, Stone R M, Cervantes F, Hochhaus A, Powell B L, Gabrilove J L, Rousselot P, Reiffers J, Cornelissen J J, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen J L, Radich J P, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson R A, and the IRIS Investigators (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355(23): 2408–2417

DOI PMID

7
Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, Zimmermann J, Lydon N B (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 2(5): 561–566

DOI PMID

8
Ernst T, Hoffmann J, Erben P, Hanfstein B, Leitner A, Hehlmann R, Hochhaus A, Müller M C (2008). ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 93(9):1389–1393

9
Ernst T, La Rosée P, Müller M C, Hochhaus A (2011). BCR-ABL mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am, 25(5): 997–1008, v–vi

DOI PMID

10
Faderl S, Jeha S, Kantarjian H M (2003). The biology and therapy of adult acute lymphoblastic leukemia. Cancer, 98(7): 1337–1354

DOI PMID

11
Gorre M E, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P N, Sawyers C L (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293(5531): 876–880

DOI PMID

12
Hochhaus A, Kreil S, Corbin A S, La Rosüe P, Müller M C, Lahaye T, Hanfstein B, Schoch C, Cross N C, Berger U, Gschaidmeier H, Druker B J, Hehlmann R (2002). Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 16(11): 2190–2196

DOI PMID

13
Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross N C, Druker B J, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton J H, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman J M (2006). Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108(1): 28–37

DOI PMID

14
Iacobucci I, Ferrarini A, Sazzini M, Giacomelli E, Lonetti A, Xumerle L, Ferrari A, Papayannidis C, Malerba G, Luiselli D, Boattini A, Garagnani P, Vitale A, Soverini S, Pane F, Baccarani M, Delledonne M, Martinelli G (2012). Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia. Blood Cancer J, 2(3): e61

DOI PMID

15
Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O’Brien S, Ravandi F, Borthakur G, Cortes J (2008). Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood, 112(1): 53–55

DOI PMID

16
Jabbour E, Soverini S (2009). Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia. Semin Hematol, 46(suppl 3): s22–26

17
Kagita S, Uppalapati S, Jiwatani S, Linga V G, Gundeti S, Nagesh N, Digumarti R (2014). Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India. Tumour Biol, 35(7): 7187–7193

DOI PMID

18
Khorashad J S, Kelley T W, Szankasi P, Mason C C, Soverini S, Adrian L T, Eide C A, Zabriskie M S, Lange T, Estrada J C, Pomicter A D, Eiring A M, Kraft I L, Anderson D J, Gu Z, Alikian M, Reid A G, Foroni L, Marin D, Druker B J, O’Hare T, Deininger M W (2013). BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood, 121(3): 489–498

DOI PMID

19
Kimura S, Ando T, Kojima K (2014). Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol, 19(1): 3–9

DOI PMID

20
La Rosée P, Deininger M W (2010). Resistance to imatinib: mutations and beyond. Semin Hematol, 47(4): 335–343

21
La Starza R, Testoni N, Lafage-Pochitaloff M, Ruggeri D, Ottaviani E, Perla G, Martelli MF, Marynen P, Mecucci C(2002). Complex variant Philadelphia translocations involving the short arm of chromosome 6 in chronic myeloid leukemia. Haematologica, 87(2):143–147

22
Maru Y (2012). Molecular biology of chronic myeloid leukemia. Cancer Sci, 103(9): 1601–1610

DOI PMID

23
Nicolini F E, Mauro M J, Martinelli G, Kim D W, Soverini S, Müller M C, Hochhaus A, Cortes J, Chuah C, Dufva I H, Apperley J F, Yagasaki F, Pearson J D, Peter S, Sanz Rodriguez C, Preudhomme C, Giles F, Goldman J M, Zhou W (2009). Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood, 114(26): 5271–5278

DOI PMID

24
O’Hare T, Shakespeare W C, Zhu X, Eide C A, Rivera V M, Wang F, Adrian L T, Zhou T, Huang W S, Xu Q, Metcalf C A 3rd, Tyner J W, Loriaux M M, Corbin A S, Wardwell S, Ning Y, Keats J A, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer T K, Dalgarno D C, Deininger M W, Druker B J, Clackson T (2009). AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 16(5): 401–412

DOI PMID

25
Quintás-Cardama A, Cortes J (2008). Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res, 14(14): 4392–4399

DOI PMID

26
Roche-Lestienne C, Laï J L, Darré S, Facon T, Preudhomme C(2003). A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N Engl J Med, 348(22): 2265–2266

DOI PMID

27
Shah N P, Tran C, Lee F Y, Chen P, Norris D, Sawyers C L (2004). Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305(5682): 399–401

DOI PMID

28
Soverini S, Iacobucci I, Baccarani M, Martinelli G (2007). Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica, 92(4): 437–439

DOI PMID

29
Tanaka R, Kimura S, Ashihara E, Yoshimura M, Takahashi N, Wakita H, Itoh K, Nishiwaki K, Suzuki K, Nagao R, Yao H, Hayashi Y, Satake S, Hirai H, Sawada K, Ottmann O G, Melo J V, Maekawa T (2011). Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. Cancer Lett, 312(2): 228–234

DOI PMID

30
Weisberg E, Manley P W, Breitenstein W, Brüggen J, Cowan-Jacob S W, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung A L, Mestan J, Daley G Q, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright R D, Gilliland D G, Griffin J D (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7(2): 129–141

DOI PMID

Outlines

/